1. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update. 2010;16(6):577-589. doi:10.1093/humupd/dmq015
2. Troude P, Bailly E, Guibert J, et al. Spontaneous pregnancies among couples previously treated by in vitro fertilization. Fertil Steril 2012; 98:63.
3. DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal Add-Back Therapy for Females Treated With Gonadotropin- Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. Obstet Gynecol 2015;126:617.
4. Roque M, Valle M, Guimarães F ,et al. Freeze-all policy: fresh vs frozen-thawed embryo transfer. Fertil Steril 2015;103:1190.
5. Yeh JS, steward RG, Dude Am, et al. Pregnancy rates in donor oocytes cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26, 457 fresh cycles from the society for Assisted Reproductive Technology. Fertil Steril 2014; 102:399.
6. Chung K, Fogle R, Bendikson K, et al. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development. Fertl Steril 2011;95:317
7. Maheswari A, Gibreel A, Siristadis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011; CD006919.
8. Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 4: CD001750.
9. Albuquerque LE, Tso LO, Saconato H, et al. Depot versus daily administration of gonadotropin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev 2013;CD002808.
10. Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2016;4: CD003719.
11. Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; CD008046.
12. Surry ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertl Steril 2019;112:298.
13. Castillo JC, Haahr T, Martínez-Moya M, Humaidan P. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Ups J Med Sci. 2020 May;125(2):131-137. doi: 10.1080/03009734.2020.1736696. Epub 2020 May 4. PMID: 32366146; PMCID: PMC7721056.